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Introduction
In normal conditions FSHR are expressed in the ovary and
the testis. It is well known that they can also be expressed
in gonadal tumours. However, recently we have found
FSHR immunopositivity in tumoral tissues of other endo-
crine tumours, namely pituitary adenomas, adrenal
tumours and neuroendocrine gut and lung tumours
(carcinoids).
The aim of this study was to see whether the same
phenomenon occurs in thyroid neoplasia.
Material and methods
Twenty three samples of surgically excised thyroids were
examined. FSHR immunostaining was performed on par-
affin sections using the rabbit anti-human FSHR polyclo-
nal antibody raised against 1-190 amino acid sequence
from the human FSH-R (sc-13935, Santa Cruz).
Results
Normal thyroid follicles do not show the immunopositivity
for FSHR. The same concerns the majority of benign
lesions, diagnosed as hyperplasia nodularis or follicular
adenoma. However, the FSHR immunostaining is partially
positive in the minority of follicles. In thyroid cancers (13
papillary cancers and one case of anaplastic thyroid can-
cer) the majority of tumoral cells exhibit the positive
FSHR immunostaining. In about one third (9/23) samples
FSHR immunoreactivity can be observed also in the
endothelia of the intrathyroidal blood vessels. This immu-
nopositivity was more frequent in the samples of thyroid
cancers (6/14) than in the benign lesions (3/9).
Conclusions
The positive FSHR immunostaining is present in thyroid
cancers, and, to a lesser degree, in benign thyroid lesions
but not in normal thyroid tissues. It suggests that aberrant
expression of FSHR is connected with thyroid neoplasia.
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